Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot, Multicenter, Randomized, Non Comparative, Double-Blind Study of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibiotic Therapy

Next Previous
Trial Profile

A Pilot, Multicenter, Randomized, Non Comparative, Double-Blind Study of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibiotic Therapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PP 1493 (Primary) ; PP 1815 (Primary) ; Antibacterials
  • Indications Bone and joint infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Acronyms PhagoDAIR; PhagoDAIR I
  • Sponsors PHAXIAM Therapeutics; Pherecydes Pharma

Most Recent Events

  • 15 May 2024 According to a PHAXIAM Therapeutics media release, company intends to capitalize on promising activity signals from real-life compassionate treatments and valuable insights from the PhagoDAIR pilot study, the data of which should be available by the end of 2024.
  • 15 May 2024 According to a PHAXIAM Therapeutics media release, this PhagoDAIR pilot study in PJI clinical data anticipated in end 2024.
  • 03 Apr 2024 This study has been Discontinued in Spain, According to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top